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Objective: To explore the effect of bortezomib on migration and invasion of cervical
carcinoma HeLa cell and speciﬁc molecular mechanism.
Methods: The effect of bortezomib on the viability of HeLa cell was measured by MTT
assay. The effect of bortezomib on cell migration and invasion was measured by
Transwell assay and invasion experiment respectively. The activation of Akt/mTOR
signaling pathway and expression level of MMP2, MMP9 were assayed by western blot.
Results: MTT assay indicated bortezomib (2.5 mM, 5 mM, 10 mM) could inhibit HeLa
cell viability, and the inhibitory rate was highest at 48 h. Transwell assay and invasion
experiment results showed that bortezomib inhibited HeLa cell migration and invasion.
Western blotting assays presented bortezomib could suppress the phosphorylation of Akt
and mTOR, and down-regulate the expression of MMP2 and MMP9.
Conclusions: These results suggested bortezomib could inhibit migration and invasion
in cervical carcinoma HeLa cell, which might be related to Akt/mTOR signal pathway.1. Introduction
Cervical cancer is one of the most common malignancies,
occupying the ﬁrst place of genitor tumor mortality rate [1]. As
same as the majority of cancer, with poor prevention and
treatment effects and more complex pathogenesis, cervical
cancer is affected by many cell signaling pathways [2]. And
the invasion and metastasis of cervical cancer is related with
Akt/mTOR signaling pathway closely [3,4]. Matrix
metalloproteinase (MMP) 2 and MMP 9 are the downstream
targets in Akt/mTOR signaling pathways. After activating Akt/
mTOR signaling pathways, MMP2 [5,6] and MMP9 [7,8] will
express persistently, then they promote the metastasis of
cervical cancer.
As a novel anti-tumor targeting drug, bortezomib can
inhibit invasiveness and migration capability of tumor,
such as cervical cancer [9], gastric cancer [10], colon cancer[11], multiple myeloma et al. [12]. It is reported that
bortezomib can down-regulate Akt/mTOR pathway, and
then inhibit migration and invasion of human multiple
myeloma RPMI8226 cell [13]. However, the speciﬁc
molecular mechanisms which bortezomib inhibit migration
and invasion of cancer cells is still unknown. The text
explores whether bortezomib can inhibit cancer cell
migration and invasion by regulating Akt/mTOR signaling
pathway or not.
2. Materials and methods
2.1. Materials
Human cervical carcinoma HeLa cells, which were cultured
in DMEM medium containing 10% fetal bovine serum, were
purchased from Cell Bank of CAS in Shanghai. Bortezomib was
purchased from Aladdin, its purity 99%. Instruments required
by this study included CO2 incubator, biochemistry incubator
(Themo Inc.), Gel imaging system (Bio-Rad Inc.), double ver-
tical electrophoresis and transferred electrophoresis (Beijing
61Instrument). Drugs and reagents required by this study
included Rabbit anti-MMP2, MMP9, Akt, p-Akt antibodyicle under the CC BY-NC-ND
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Technology); Transwell chambers (Corning Inc.), b-actin
(Beyotime Biotechnology Institute), FBS, DMEM medium and
tetrazolium (MTT) (Gibco Inc.).2.2. MTT assay
Cervical cancer HeLa cells were digested in the logarithmic
growth phase, the concentration was adjusted. They were inoc-
ulated, and incubated for 24 h in 5% CO2 incubator at 37 C.
DMEM containing 5% fetal calf serum was added. Then they
were placed in bortezomib medium (ﬁnal concentration 2.5 mM,
5 mM, 10 mM) and culture for 24 h. At last 20 mL (5 mL) MTT
was added, 4 h later, the supernatant was discarded, and then
150 mL DMSO was dropped into each hole. After 10 min, the
OD was measured at 570 nm ELIASA. And then cellular pro-
liferation inhibition rate was calculated.2.3. Cell migration assay
Cervical cancer HeLa cells was digested in the logarithmic
growth phase, the concentration was adjusted to 8 × 103 cells/
mL, and inoculated in 6-well plates. They were incubated for
24 h in 5% CO2 incubator at 37 C. Secondly, DMEM con-
taining 5% fetal calf serum was added, and were placed in
bortezomib medium (ﬁnal concentration 2.5 mM, 5 mM, 10 mM)
and cultured for 48 h. Cells were digested and added into the
upper Transwell and lower Transwell chamber with DMEM
medium containing 5% fetal bovine serum, and were cultured
for 24 h. And Transwell chamber was taken out, washed, ﬁxed
by paraformaldehyde, stained with crystal violet. At last the
number of cell permeating septum was counted in 5 ﬁelds of
microscope of inverted optical microscope. The average number
of cells per ﬁeld was calculated, which represent the ability of
cells to migrate.
2.4. Cell invasion assay
Matrigel glue was spread evenly on the micro-ﬁlm of
Transwell chamber as a gel spare. Other steps were same as the
ones in 2.2. The average number of cells per ﬁeld was calcu-
lated, which represents the ability of cells to migrate.
2.5. Western blot
Cells were collected. And collected protein sample was
splitted. BCA kit was used to detect protein concentrations.
Samples were loaded. And SDS gel electrophoresis was carried
out, transferred to membranes, closed, and then added withTable 1
Effect of bortezomib on viability of cervical carcinoma HeLa cell (mean ± S
Group Dose (mM)
24 h
Control group 0.0 0.12 ± 0.05
Bortezomib 2.5 3.89 ± 0.30
5.0 9.91 ± 1.46
10.0 20.65 ± 4.61
Compared with control group, *P < 0.05, **P < 0.01.primary antibodies for incubation overnight at 4 C. The next
day, second antibody was added for incubation and exposure.
“Quantity one” software was used to analyze gray value of
protein.
2.6. Statistical analysis
All data were repeated for three times at least. And they were
represented as mean ± SD. Difference was analyzed between
two groups by t-test. P < 0.05 was regarded as signiﬁcant dif-
ference. At last, all the data were analyzed by using SPSS 17.0
statistical analysis software.
3. Results
3.1. Effect of bortezomib on viability in cervical
carcinoma HeLa cell
As shown in Table 1, with the concentration increasing,
inhibitory effect of bortezomib on HeLa cell activity was also
gradually increased. At 10 mM, inhibition rate was highest. At
the same concentration, as time passing by, inhibitory effect was
gradually increased. Considering the similar efﬁcacies at 48 and
72 h, so in subsequent experiments 48 h was selected as
administration time.
3.2. Effect of bortezomib on migration and invasion in
cervical carcinoma HeLa cell
As shown in Table 2, after administration of 2.5 mM, 5 mM
and 10 mM bortezomib, the number of cells passing ﬁlms and
entering the lower chamber was decreased signiﬁcantly (P < 0.0
or 0.05). It suggested that bortezomib could inhibit migration
and invasion of HeLa cells in a dose-dependent manner.
3.3. Effect of bortezomib on Akt/mTOR signaling
pathway in HeLa cell
As shown in Figure 1, compared with control group, borte-
zomib could inhibit Akt and mTOR phosphorylation in a dose-
dependent manner (P < 0.05). And bortezomib had no effect on
the expressions of Akt and mTOR.
3.4. Effect of bortezomib on the expression of MMP in
cervical carcinoma HeLa cell
As shown in Figure 2, compared with control group, borte-
zomib could inhibit the expression of MMP2 and MMP9 in
time-independent manner (P < 0.05).D).
Inhibition ratio (%)
48 h 72 h
3.21 ± 0.34 3.18 ± 0.51
* 30.56 ± 3.12** 31.76 ± 2.43**
* 44.37 ± 4.10** 44.19 ± 3.28**
** 59.39 ± 5.45** 59.76 ± 5.72**
Table 2
Effect of bortezomib on migration and invasion in HeLa cell (mean ± SD).
Classiﬁcation Control group Bortezomib (mM)
2.5 5 10
Migration 98.00 ± 9.78 86.21 ± 3.97* 53.41 ± 3.54** 32.00 ± 4.57**
Invasion 98.00 ± 8.69 86.34 ± 3.65 52.38 ± 5.66** 30.66 ± 5.61**
Compared with control group, *P < 0.05, **P < 0.01.
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Migration and invasion are important biological habits of
malignant tumor cells. They are also the main reason for the
fatality rate of tumor patients. Inhibition of tumor cell migration
and invasion can effectively improve the survival rate of pa-
tients. It has been reported that bortezomib can inhibit migration
and invasion in variety of tumor cells [9–12]. The experiment also
ﬁnds that bortezomib signiﬁcantly inhibit migration and
invasion of HeLa cells in a dose-dependent manner after
administration for 48 h.
Akt is an important serine kinases, which located at down-
stream of PI3K, also a key signaling molecule which can pro-
mote cell growth and maintain normal function., Akt
phosphorylation levels which in normal cervix, cervical intra-
epithelial neoplasia, and positive expression rate in cervical
squamous tissue gradually increase [14]. The enhancement of
cervical cancer cell invasion capacity is related with activation
of Akt. Akt inhibitor can signiﬁcantly inhibit the migration
and invasion of HeLa cells [15,16]. Activated Akt can make
Ser939 sites and THrl462 sites phosphorylated on TSC-2. And
then indirectly or directly activate mTOR, promoting the inva-
sion of various tumor cells, including cervical cancer cells [3,4].Figure 1. Effect of bortezomib on Akt/mTOR signaling pathway in cer-
vical carcinoma HeLa cell. Compared with control group, *P < 0.05,
**P < 0.01, ##P < 0.01.mTOR is an atypical serine/threonine protein kinase comprised
by more than 2000 amino acids, which can make threonine
phosphorylation and is also one member of PI3K family. Akt/
mTOR signaling pathway activation is closely related with
development of metastasis in breast cancer [17], melanoma
[18,19], pancreatic cancer [20,21], cervical cancer [3,4]. In up to
95% of cervical cancer tissue, there is mTOR signaling
pathway activation which plays an important role in the
development of cervical cancer [22]. Xie [3], Roy [4] et al. have
conﬁrmed that inhibiting Akt/mTOR signaling pathway which
can signiﬁcantly inhibit the migration and invasion of HeLa
cells. This experiment has also proved that it can signiﬁcantly
inhibit Akt and mTOR phosphorylation and then inhibiting
cell migration and invasion after bortezomib affecting HeLa
cells.
Destruction of tissue basement membrane and degradation of
extracellular matrix are essential to tumor cell invasion, which
usually are achieved by proteolytic MMPs. MMP2 is a proteo-
lytic enzyme depending on zinc ion, which can be secreted by
various of cells, can degrade extracellular matrix and basement
membrane components. And then destroy local tissue structure
and increase tumor-induced angiogenesis. Therefore it can play
an important role in various stages of tumor development and
invasion [23]. MMP9 is an enzyme with largest molecular
weight, which can degrade extracellular matrix components
and promote cancer cells to invade surrounding normal tissue,Figure 2. Effect of bortezomib on the expression of MMPs in cervical
carcinoma HeLa cell. Compared with control group, **P < 0.01,
#P < 0.05, ##P < 0.01.
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expressions of MMP2 and MMP9 in cervical cancer patients
are higher than the ones in normal cervical tissues. Therefore
they play important roles in development, invasion and
metastasis of cervical cancer. And they are positively
correlated with tumor invasion and metastasis [25,26].
Meanwhile, the overexpression of MMP2 and MMP9 are
correlated with poor prognosis of cervical cancer [27]. This
study has found that in HeLa cells, with increasing of the
administered concentration of Bortezomib, MMP2 and MMP9
expression have been signiﬁcantly inhibited.
In summary, bortezomib can inhibit the expression of MMP2
and MMP9 by blocking Akt/mTOR signaling pathway. And
then it can inhibit the migration and invasion of HeLa cells.
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